Wegovy

2022 - 12 - 12

Post cover
Image courtesy of "Axios"

The growing market for weight loss drugs (Axios)

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among ...

[the Wall Street Journal reported](https://www.wsj.com/articles/why-you-cant-find-wegovy-the-weight-loss-drug-11670108199). [per the CDC](https://www.cdc.gov/obesity/about-obesity/why-it-matters.html#:~:text=Children%20with%20obesity%20are%20more%20likely%20to%20have%20obesity%20as%20adults.&text=Obesity%20costs%20the%20US%20healthcare%20system%20nearly%20%24173%20billion%20a%20year). The bottom line: More effective solutions in the fight against obesity may finally be arriving. Most of the treatments can cost upwards of $1,000 a month or more out of pocket. Currently, much of the coverage is limited to those with diabetes. [CBS News](https://www.cbsnews.com/news/ozempic-wegovy-weight-loss-drugs-shortage-prescriptions/). Novo Nordisk is projected to capture the largest share with Wegovy sales topping $7 billion. There's also a drug known as tirzepatide, sold by Eli Lilly under the brand name Mounjaro. [NBC News](https://www.nbcnews.com/health/health-news/new-weight-loss-drugs-effective-insurance-coverage-shortage-rcna32781). [weight loss drug candidate](https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-says-experimental-obesity-drug-has-promising-durability-2022-12-03/). Revolutionary." The condition is estimated to cost the U.S.

Obesity Drug Wegovy's European Rollout Delayed After US ... (BNN)

(Bloomberg) -- Novo Nordisk is delaying introduction of its Wegovy obesity treatment in Europe until next year to make sure it has enough supply after the ...

In the UK alone, the cost of obesity is estimated at £9.7 billion ($11.9 billion) by 2050, Novo Nordisk estimates. If Novo Nordisk can keep the advantage, the market is there for the taking, with global sales estimated to reach more than $50 billion by 2030, according to Morgan Stanley. Novo Nordisk aims for global sales of the drug to exceed 25 billion kroner ($3.5 billion) by that year. While obesity has the potential to be major business for Novo Nordisk, Wegovy’s limited supply has become a lesson for drugmakers about runaway demand. are revitalizing the field by re-purposing diabetes drugs. Overweight and obese patients had an average weight loss of 15% in clinical trials.

Post cover
Image courtesy of "Bloomberg"

Obesity Drug Wegovy's European Rollout Delayed After US Setbacks (Bloomberg)

Novo Nordisk is delaying introduction of its Wegovy obesity treatment in Europe until next year to make sure it has enough supply after the US launch was ...

Explore the last week